Sartorius Aktiengesellschaft (ETR:SRT) used its 2025 Capital Markets Day in Göttingen to outline strategic priorities, discuss midterm targets, and provide additional context on market conditions, technology investment and operational initiatives. The event brought together the executive board of CEO Michael Grosse, Lab Products & Services (LPS) division head Alexandra Gatzemeyer, Bioprocess Solutions (BPS) division head and Sartorius Stedim Biotech CEO René Fáber, and CFO Florian Funck.
CEO highlights: strategy review and guidance philosophy
Grosse, who joined as CEO in July 2025, said he has been most impressed by the company’s people, describing a culture tied to the purpose of “better health for more people” and a drive to find “a new answer to new questions as much as a new answer to existing questions.” He also pointed to rising customer pressures—ranging from affordability and speed of drug development to regulatory complexity and geopolitical uncertainty—as an opportunity for Sartorius to move closer to customers as a “trusted partner” delivering “speed, reliability and quality.”
Grosse also outlined what he called a balanced approach to guidance: not overly aggressive and not overly conservative, with an aim to deliver predictability “quarter by quarter, year on year.”
Track record, footprint and innovation approach
Funck reviewed the company’s long-term trajectory, noting a 10-year sales CAGR of 12% and an operating margin increase of roughly 600 basis points over 10 years. He said more than 80% of sales are now tied to life science customers. Funck emphasized Sartorius’ global footprint and cited key manufacturing sites including Puerto Rico and Songdo, South Korea, which is under construction and planned to come online in early 2027.
Grosse described innovation leadership as central to Sartorius’ model, saying acquisitions are intended to add technology rather than revenue. He outlined portfolio development across early-stage drug discovery and development (bioanalytics), upstream and downstream bioprocessing (including the addition of chromatography), and preparation for “advanced therapies” such as cell and gene therapies and nucleic acids. He highlighted collaborations including work with Sanofi on the “Pionic” platform and a collaboration with NVIDIA focused on artificial intelligence and data analytics.
End-to-end offering and recurring revenue model
Management emphasized the breadth of Sartorius’ portfolio across molecule development, process development, clinical manufacturing and commercial production, describing the business as “sticky” with an “80% level of recurring revenues.” Grosse said the company increasingly views software and data-driven “insights” as value-creating elements alongside consumables and service, with an ambition to orchestrate manufacturing processes and ultimately move toward “autonomous manufacturing” enabled by models and analytics.
Gatzemeyer presented LPS as a workflow-driven offering designed to accelerate drug development and improve decision-making earlier in R&D. She cited examples including connected bioanalytical instruments (Incucyte, Octet, CellCelector and iQue). She described AI-powered modules on the Incucyte platform developed in collaboration with NVIDIA, and noted the launch of an Incucyte version with a confocal microscope to support 3D imaging of organoids.
Fáber described bioprocessing as a race to develop scalable and efficient manufacturing, highlighting automation in process development, including the company’s ambr cell culture robotic system. He discussed long-term improvements in monoclonal antibody manufacturing efficiency and said the company sees opportunities to unlock additional value by combining technologies into more efficient manufacturing lines.
Market outlook and growth drivers
Management discussed structural demand drivers including demographics, a broader pharmaceutical market growing about 5% annually, and biologics gaining share. Grosse said Sartorius projects biologics could represent 57% of the overall pharma market by 2030. He also pointed to a pipeline of roughly 26,000 molecules in research and development, saying nearly half are next-generation antibodies and advanced therapies.
Funck provided market growth estimates for Sartorius’ addressable markets:
- BPS market growth: 8%–10%
- LPS market growth: 4%–6%
- Blended group market growth: 7%–9%
Management said key market drivers include customer production volumes and increasing modality diversity and complexity. They also acknowledged challenges such as drug-pricing pressure and rising volatility from geopolitical and policy shifts, arguing that cost pressure on customers can increase demand for advanced technologies.
Fáber reviewed the evolution of single-use technologies, stating clinical manufacturing penetration is about 85% while commercial penetration is “much less than 20%,” which he characterized as an upside opportunity. He also said the mix of pipeline modalities—including ADCs and other next-gen antibodies and lower-volume products such as cell and gene therapies—supports further adoption of single-use and process intensification.
Midterm targets, margin bridge and capital allocation
Grosse said 2026 remains a “transitional period” before a return to “traditional growth levels,” with the company expecting a more normalized market in 2027. He described improving conditions in equipment demand as a key driver, alongside “slight improvements” in China and a more positive funding sentiment in biotech versus earlier periods.
Management reiterated midterm organic growth ambitions of:
- BPS: 9%–12%
- LPS: 5%–7%
- Group: 8%–11% (100–200 basis points above market)
On profitability, Funck said margin expansion is expected to be supported by operational leverage, gross margin improvement, productivity initiatives and simplification. He addressed comparisons of reported gross margins versus 2019, noting that accounting-related amortization from M&A weighs on externally reported margins by roughly 260–280 basis points between 2019 and 2025. Beyond that, he cited two additional drags: investments and added capacity built ahead of growth, and ongoing inventory clean-up related to pandemic-era buildups and shelf-life effects.
Funck said the company expects its group EBITDA margin to expand by 50–75 basis points, supported by continuous improvement efforts following the “Fit for Future” efficiency program and a “stretch” cost-reduction mindset. He also said Sartorius is deliberately maintaining R&D investment to support technology leadership.
On capital spending, Funck said Sartorius invested €2.6 billion from 2020 to 2025 and described Songdo as the last major capacity build in this cycle, with the facility expected online at the end of 2026 or early 2027. He said CapEx is expected to normalize toward historical levels of about 9% of turnover by 2028 (including maintenance, growth CapEx and capitalized R&D under IFRS). He also said the company remains committed to deleveraging and maintaining an investment-grade rating, and expects dividend payout to remain broadly in line with prior years’ payout ratios based on underlying EPS.
In Q&A, management said it aims to deliver within the midterm corridor in 2027, though it did not provide explicit 2027 guidance. Funck said Q1 was developing in line with expectations and noted FX headwinds that he expected to be more pronounced in Q1, while reiterating comfort with guidance and flagging that tariffs were a new year-over-year factor compared with Q1 of the prior year.
About Sartorius Aktiengesellschaft (ETR:SRT)
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers.
